Kopp Investment Advisors LLC decreased its stake in Omnicell, Inc. (NASDAQ:OMCL) by 4.0% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 68,841 shares of the company’s stock after selling 2,886 shares during the period. Omnicell accounts for approximately 3.3% of Kopp Investment Advisors LLC’s holdings, making the stock its 8th largest position. Kopp Investment Advisors LLC owned approximately 0.18% of Omnicell worth $3,339,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors also recently made changes to their positions in the company. BlackRock Inc. grew its holdings in shares of Omnicell by 4.0% in the 4th quarter. BlackRock Inc. now owns 4,839,191 shares of the company’s stock valued at $234,701,000 after acquiring an additional 187,069 shares in the last quarter. Conestoga Capital Advisors LLC grew its holdings in shares of Omnicell by 10.8% in the 4th quarter. Conestoga Capital Advisors LLC now owns 1,792,313 shares of the company’s stock valued at $86,927,000 after acquiring an additional 174,607 shares in the last quarter. Eagle Asset Management Inc. grew its holdings in shares of Omnicell by 36.8% in the 4th quarter. Eagle Asset Management Inc. now owns 1,365,794 shares of the company’s stock valued at $66,047,000 after acquiring an additional 367,687 shares in the last quarter. Carillon Tower Advisers Inc. bought a new position in shares of Omnicell in the 4th quarter valued at about $38,612,000. Finally, Fisher Asset Management LLC grew its holdings in shares of Omnicell by 0.3% in the 4th quarter. Fisher Asset Management LLC now owns 530,569 shares of the company’s stock valued at $25,733,000 after acquiring an additional 1,650 shares in the last quarter.
Shares of Omnicell, Inc. (OMCL) opened at $44.40 on Monday. Omnicell, Inc. has a one year low of $36.95 and a one year high of $55.40. The stock has a market cap of $1,721.98, a PE ratio of 87.06, a P/E/G ratio of 3.66 and a beta of 0.75. The company has a quick ratio of 1.28, a current ratio of 1.73 and a debt-to-equity ratio of 0.38.
OMCL has been the subject of several analyst reports. BidaskClub cut Omnicell from a “sell” rating to a “strong sell” rating in a report on Friday, January 19th. Zacks Investment Research upgraded Omnicell from a “strong sell” rating to a “hold” rating in a report on Wednesday, December 27th. Oppenheimer restated a “buy” rating and issued a $55.00 price objective on shares of Omnicell in a report on Monday, January 29th. Cantor Fitzgerald restated a “buy” rating and issued a $63.00 price objective on shares of Omnicell in a report on Thursday, February 1st. Finally, Craig Hallum cut Omnicell from a “buy” rating to a “hold” rating in a report on Friday, February 2nd. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and five have issued a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus price target of $56.14.
In related news, Chairman Randall A. Lipps sold 8,186 shares of the firm’s stock in a transaction dated Tuesday, March 6th. The shares were sold at an average price of $44.21, for a total value of $361,903.06. Following the completion of the sale, the chairman now directly owns 224,206 shares in the company, valued at approximately $9,912,147.26. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Peter J. Kuipers sold 1,926 shares of the firm’s stock in a transaction dated Monday, December 18th. The shares were sold at an average price of $51.69, for a total transaction of $99,554.94. Following the completion of the sale, the chief financial officer now owns 40,544 shares of the company’s stock, valued at $2,095,719.36. The disclosure for this sale can be found here. Company insiders own 3.77% of the company’s stock.
Omnicell Company Profile
Omnicell, Inc provides automation and business analytics software solutions for patient-centric medication and supply management across the entire healthcare continuum, from the acute care hospital setting to post-acute skilled nursing and long-term care facilities to the home. It operates through two segments: Automation and Analytics, and Medication Adherence.
Want to see what other hedge funds are holding OMCL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Omnicell, Inc. (NASDAQ:OMCL).
Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.